Orbimed Advisors LLC Applied Therapeutics Inc. Transaction History

Orbimed Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.54 - $1.12 $647,502 - $1.34 Million	-1,199,079 Reduced 28.21%	3,050,921 $2.32 Million
Q2 2022 Aug 15, 2022	BUY	$0.76 - $2.64 $3.23 Million - $11.2 Million	4,250,000 New	4,250,000 $4.03 Million
Q1 2022 May 16, 2022	SELL	$1.48 - $6.22 $3.42 Million - $14.4 Million	-2,313,681 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.77 - $18.29 $493,698 - $1.03 Million	56,294 Added 2.49%	2,313,681 $20.7 Million
Q1 2021 May 17, 2021	BUY	$16.57 - $28.65 $8.05 Million - $13.9 Million	485,556 Added 27.4%	2,257,387 $42.3 Million
Q4 2020 Feb 16, 2021	BUY	$15.44 - $24.23 $3.48 Million - $5.46 Million	225,144 Added 14.56%	1,771,831 $39 Million
Q3 2020 Nov 16, 2020	BUY	$19.43 - $35.36 $6.39 Million - $11.6 Million	329,009 Added 27.02%	1,546,687 $32.1 Million
Q2 2020 Aug 14, 2020	SELL	$29.41 - $51.23 $3.01 Million - $5.24 Million	-102,199 Reduced 7.74%	1,217,678 $44 Million
Q1 2020 May 15, 2020	BUY	$19.54 - $55.47 $6.5 Million - $18.5 Million	332,691 Added 33.7%	1,319,877 $43.1 Million
Q4 2019 Feb 14, 2020	BUY	$10.16 - $28.14 $10 Million - $27.8 Million	987,186 New	987,186 $26.9 Million

140

112M

1.68M

1.91M

Ticker APLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,700
Market Cap $42.3M
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.